For that reason and considering the high cost, TNF-α therapy in PMR and GCA seems justified solely when these diseases can only be controlled by GC doses that are untenable due to serious adverse effects and comorbidities induced or worsened by steroids. The gene discussed is TNF; the disease is temporal arteritis.